Smoking is a well-known risk factor for disease severity and complications in Crohn’s disease (CD). Despite being identified as a quality measure, little has been studied on promoting smoking cessation in CD. We recently showed that providing nicotine replacement (NRT) in the IBD clinic was effective but limited by low rates of participation. The nicotine metabolite ratio (NMR) is a biomarker of nicotine metabolism that predicts odds of cessation and response to varenicline. The aim of this study was to evaluate the feasibility of and engagement in a personalized smoking cessation program using NMR in an IBD clinic.